| abstract |
A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R 1 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and R 2 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and wherein the phosphatidylcholine product (PC) contains the following amounts of fatty acids: 55-72 linoleic acid; 10 18 palmitic acid; 07 15 oleic acid; 02 08 linolenic acid; 02 08 stearic acid, and at least one excipient for delayed release, can be used for the improved treatment of ulcerative colitis. |